InvestorsHub Logo
Followers 166
Posts 19825
Boards Moderated 2
Alias Born 12/09/2004

Re: Hazel2323 post# 439565

Tuesday, 11/21/2023 8:03:58 AM

Tuesday, November 21, 2023 8:03:58 AM

Post# of 462963
Based on the information provided by boi568, I would expect the FDA application for AD to be in process and possibly approved before the EMA application.

Seems to me that an application in Australia for AD will be next up. Looks like the AU procedures are faster.

a pre-submission planning phase where applicants lodge details of a proposed application at least 2¼ months prior to lodgement of the dossier allowing the TGA to identify milestone dates and plan resource requirements (this is not required for submissions lodged in eCTD format if the sponsor selects the PPF-only option)



If that is accepted the evaluation process starts. Typically taking 10.5 months.
There is a priority review process in AU that reduces the approval time line to 150 working days vs 220 working days.

2.4.5 Priority review designated applications
TGA now has a formal Priority review pathway for faster assessment of vital and life-saving prescription medicines for which a complete data dossier is available. The target timeframe of 150 working days is up to three months shorter than the standard prescription medicines registration process. A valid Priority review designation must be held in order to access the Priority review pathway.[/quo
Based on the eligibility requirements it appears that Anavex is eligible for priority review but Anavex must apply for that designation.


The real folly is ignoring the progress the company has made.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News